Spring Bank Pharmaceuticals (NASDAQ:SBPH)‘s stock had its “buy” rating reissued by stock analysts at Dawson James in a report released on Monday, Zacks.com reports. Dawson James also issued estimates for Spring Bank Pharmaceuticals’ Q2 2019 earnings at ($0.52) EPS, Q3 2019 earnings at ($0.53) EPS, Q4 2019 earnings at ($0.54) EPS and FY2019 earnings at ($1.92) EPS.

Several other research firms have also commented on SBPH. ValuEngine lowered Spring Bank Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, May 1st. Zacks Investment Research lowered Spring Bank Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, March 14th. Cantor Fitzgerald set a $29.00 price target on Spring Bank Pharmaceuticals and gave the stock a “buy” rating in a report on Friday, April 12th. Finally, Chardan Capital set a $25.00 price target on Spring Bank Pharmaceuticals and gave the stock a “buy” rating in a report on Friday, April 12th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the company’s stock. Spring Bank Pharmaceuticals has an average rating of “Buy” and an average price target of $23.80.

Shares of NASDAQ SBPH traded down $0.31 during trading on Monday, hitting $7.05. 144 shares of the company were exchanged, compared to its average volume of 32,027. Spring Bank Pharmaceuticals has a 12-month low of $6.30 and a 12-month high of $15.00. The firm has a market cap of $115.92 million, a PE ratio of -3.77 and a beta of 0.53.

Spring Bank Pharmaceuticals (NASDAQ:SBPH) last posted its quarterly earnings results on Monday, April 29th. The company reported ($0.32) EPS for the quarter, topping the consensus estimate of ($0.52) by $0.20. As a group, equities research analysts expect that Spring Bank Pharmaceuticals will post -2.13 earnings per share for the current fiscal year.

In related news, insider Martin J. Driscoll acquired 10,000 shares of Spring Bank Pharmaceuticals stock in a transaction that occurred on Tuesday, April 30th. The shares were purchased at an average cost of $7.34 per share, for a total transaction of $73,400.00. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. 15.60% of the stock is currently owned by insiders.

A number of institutional investors and hedge funds have recently modified their holdings of the stock. BlackRock Inc. raised its holdings in Spring Bank Pharmaceuticals by 1.4% in the 1st quarter. BlackRock Inc. now owns 684,927 shares of the company’s stock valued at $7,184,000 after buying an additional 9,594 shares during the period. Vanguard Group Inc raised its holdings in Spring Bank Pharmaceuticals by 34.8% in the 3rd quarter. Vanguard Group Inc now owns 549,186 shares of the company’s stock valued at $6,618,000 after buying an additional 141,730 shares during the period. Vanguard Group Inc. raised its holdings in Spring Bank Pharmaceuticals by 34.8% in the 3rd quarter. Vanguard Group Inc. now owns 549,186 shares of the company’s stock valued at $6,618,000 after buying an additional 141,730 shares during the period. Northern Trust Corp raised its holdings in Spring Bank Pharmaceuticals by 7.2% in the 1st quarter. Northern Trust Corp now owns 184,064 shares of the company’s stock valued at $1,931,000 after buying an additional 12,314 shares during the period. Finally, Geode Capital Management LLC grew its position in Spring Bank Pharmaceuticals by 8.7% in the 4th quarter. Geode Capital Management LLC now owns 116,861 shares of the company’s stock valued at $1,214,000 after acquiring an additional 9,398 shares in the last quarter. Hedge funds and other institutional investors own 43.08% of the company’s stock.

Spring Bank Pharmaceuticals Company Profile

Spring Bank Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers and develops therapeutics for the treatment of viral infections, inflammatory diseases, and various cancers using small molecule nucleotide platform. Its lead product candidate is inarigivir soproxil for the treatment of chronic hepatitis B virus (HBV).

Recommended Story: Trade Deficit

Analyst Recommendations for Spring Bank Pharmaceuticals (NASDAQ:SBPH)

Receive News & Ratings for Spring Bank Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spring Bank Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.